Semaglutide and tirzepatide cardiovascular outcomes: real-world data

TL;DR

A November 2025 Nature Medicine study of over 800,000 U.S. patients found that semaglutide and tirzepatide offer comparable protection against heart attack, stroke, and death - meaning the choice between them for cardiovascular benefit comes down to individual factors, not one drug's clear superiority.

Randomised trials establish whether a drug works. Real-world studies tell you whether it keeps working when it leaves the controlled trial environment and enters the hands of actual patients, with all their complexity. That is the value of a large-scale analysis published in Nature Medicine in November 2025 - and with 800,000+ patient records across three insurance databases, it is one of the most comprehensive real-world comparisons of GLP-1 medications and heart outcomes produced to date.

How the study was designed

Researchers at Brigham and Women's Hospital and Harvard Medical School led the analysis, drawing on U.S. insurance claims data from three databases - Medicare, Optum Clinformatics, and Merative MarketScan - covering the years 2018 to 2025. The research followed a "benchmark, expand, and compare" methodology designed to increase confidence in the findings:

• First, they emulated the design of established cardiovascular outcome trials (SUSTAIN-6 for semaglutide, SURPASS-CVOT for tirzepatide) using the same patient criteria - to verify that the real-world data would reproduce trial results they already knew
• Then they expanded those analyses to reflect broader clinical practice populations
• Finally, they ran a direct head-to-head comparison of tirzepatide versus semaglutide in 297,842 patients who had started one of the two drugs

This layered approach matters because a study that cannot reproduce known trial results is unreliable for generating new comparisons. The benchmark step passed - the real-world data accurately reflected what the randomised trials had shown. That makes the head-to-head findings more credible.

What semaglutide did for the heart

In the expanded population comparing semaglutide to sitagliptin (a common diabetes drug with no cardiovascular benefit), 453,201 patients were analysed. The primary composite endpoint was myocardial infarction or stroke.

Semaglutide reduced that composite risk with a hazard ratio of 0.82 (95% CI: 0.74-0.91). In plain terms: semaglutide users had an 18% lower risk of heart attack or stroke compared to sitagliptin users. The one-year risk was 1.5% on semaglutide versus 1.7% on sitagliptin. Both heart attack (HR 0.81) and stroke (HR 0.84) contributed to that reduction individually.

The heart failure finding was even more striking. Semaglutide reduced hospitalisation for heart failure versus sitagliptin by 39% (HR 0.61, 95% CI: 0.57-0.66). This matches and extends the SELECT trial's cardiovascular data, which led to Wegovy's FDA-approved cardiovascular indication.

What tirzepatide did for the heart

Tirzepatide was compared first to dulaglutide (another GLP-1 receptor agonist), then directly to semaglutide. Against dulaglutide, tirzepatide reduced the composite endpoint of MI, stroke, or all-cause death with a hazard ratio of 0.87 (95% CI: 0.75-1.01). The one-year risk was 1.4% on tirzepatide versus 1.8% on dulaglutide.

Against semaglutide directly - the comparison most patients want to know about - tirzepatide showed a hazard ratio of 1.06 (95% CI: 0.95-1.18). One-year risk was 1.3% for both drugs. The confidence interval crosses 1.0, which means this result is statistically consistent with no difference between the two drugs for the primary endpoint.

The heart failure comparison showed tirzepatide with a hazard ratio of 0.91 versus semaglutide (95% CI: 0.81-1.01) - again statistically similar, though with a numerical trend favouring tirzepatide that researchers noted is worth watching in future studies.

What "comparable" actually means in practice

The headline finding - that both drugs provide comparable cardiovascular protection in real-world patients - deserves some careful interpretation. It does not mean the drugs are identical. Semaglutide has a randomised trial (SELECT) that directly demonstrated cardiovascular benefit, and that evidence is more robust by design than observational data alone. Tirzepatide's cardiovascular outcome trial is still ongoing.

What the Nature Medicine study adds is reassurance that in the messy real world, where patients miss doses, switch medications, and have a dozen comorbidities not in any trial protocol, tirzepatide appears to produce cardiovascular outcomes consistent with what semaglutide produces. That gap in trial evidence is closing.

For the 297,842 patients in the direct head-to-head comparison, both drugs brought the one-year composite risk to 1.3%. The difference between 1.3% and 1.3% is not clinically meaningful. Where you might see divergence is in longer follow-up, in patients with very high cardiovascular risk, or in people with heart failure specifically - where tirzepatide's 9% numerical advantage (HR 0.91) may or may not become statistically significant with more data.

Who was studied and what that means for you

The study population had a mean age of 59-69 years depending on the cohort, 50-56% female, and a BMI of 34.5-38.7 kg/m². The majority had type 2 diabetes, which is the primary indication for both drugs in many of these insurance claims. That is an important distinction from the SURMOUNT-5 trial, which enrolled people without diabetes.

If you have type 2 diabetes and established cardiovascular disease, both semaglutide and tirzepatide now have strong real-world evidence supporting heart protection. If you have obesity without diabetes and are on GLP-1 medications primarily for weight loss, semaglutide has the more established cardiovascular benefit - but real-world data increasingly suggests tirzepatide is not behind.

The nutrient side of cardiac health on GLP-1 medications

One dimension the cardiovascular trials do not address is what happens to the micronutrients that support heart function as food intake drops on GLP-1 medications. Magnesium supports normal heart rhythm. Omega-3 fatty acids affect cardiovascular inflammation. Vitamin D plays a role in cardiac muscle function.

A February 2026 meta-analysis found that 13.6% of GLP-1 users developed vitamin D deficiency, and 64% showed insufficient iron levels over time - both of which have downstream effects on energy, fatigue, and for iron, cardiovascular oxygen delivery. The drugs' cardiovascular benefits are real and documented. But the nutritional gaps that come alongside reduced appetite are worth monitoring too. At GLP-1 Shield, we track the specific deficiencies GLP-1 users face and formulate around them.

Frequently asked questions

Does tirzepatide protect the heart as well as semaglutide?

Based on the Nature Medicine real-world study of 297,842 patients, tirzepatide and semaglutide produced identical one-year composite cardiovascular event rates (1.3% each). The hazard ratio was 1.06 with a confidence interval crossing 1.0 - statistically, no meaningful difference was detected. Semaglutide has a completed randomised cardiovascular outcome trial (SELECT); tirzepatide's is ongoing.

What cardiovascular events do these drugs reduce?

Both drugs are associated with reductions in heart attack, stroke, and hospitalisation for heart failure in people with type 2 diabetes. Semaglutide's SELECT trial showed a 20% reduction in major adverse cardiovascular events (MACE) in people with obesity and established cardiovascular disease, leading to an FDA-approved indication for this use.

Can I take semaglutide if I have heart disease?

Semaglutide (as Wegovy) has an FDA-approved indication specifically to reduce major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease. This makes it one of the few weight-loss medications explicitly indicated for heart disease patients. Always discuss your specific history with your prescriber.

Does losing weight on GLP-1 medications account for most of the heart benefit?

Not entirely. The cardiovascular benefits of semaglutide in the SELECT trial were seen independent of the degree of weight loss, suggesting direct effects on inflammation, blood pressure, and lipid metabolism beyond just the weight-related improvement. Researchers are still investigating the precise mechanisms behind the heart protection.